MX2020006105A - Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. - Google Patents

Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.

Info

Publication number
MX2020006105A
MX2020006105A MX2020006105A MX2020006105A MX2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A MX 2020006105 A MX2020006105 A MX 2020006105A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
atopic dermatitis
formulations
peptide immunogen
Prior art date
Application number
MX2020006105A
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2020006105A publication Critical patent/MX2020006105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente descripción está dirigida a construcciones de inmunógenos peptídicos individuales dirigidas a porciones de la proteína Interleucina-31 (IL-31) para el tratamiento y/o la prevención de una afección pruriginosa y/o afección alérgica, como la dermatitis atópica. La presente descripción también se dirige a composiciones que contienen las construcciones de inmunógenos peptídicos, métodos de fabricación y uso de las construcciones de inmunógenos peptídicos y anticuerpos producidos por las construcciones de inmunógenos peptídicos.
MX2020006105A 2017-12-11 2018-12-11 Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. MX2020006105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597130P 2017-12-11 2017-12-11
PCT/US2018/065025 WO2019118512A2 (en) 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2020006105A true MX2020006105A (es) 2020-11-09

Family

ID=66820956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006105A MX2020006105A (es) 2017-12-11 2018-12-11 Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.

Country Status (12)

Country Link
US (1) US20210079054A1 (es)
EP (1) EP3724218A2 (es)
JP (1) JP7250032B2 (es)
KR (1) KR20210009296A (es)
CN (1) CN111448208B (es)
AU (1) AU2018383708B2 (es)
BR (1) BR112020011308A2 (es)
CA (1) CA3085318A1 (es)
MX (1) MX2020006105A (es)
SG (1) SG11202005526WA (es)
TW (1) TWI741241B (es)
WO (1) WO2019118512A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
MX2020009639A (es) 2018-03-16 2021-01-08 Zoetis Services Llc Vacunas de peptídos contra interleucina-31.
MX2022002360A (es) * 2019-08-29 2022-04-06 Kindred Biosciences Inc Anticuerpos de anti-il31 para uso veterinario.
CN116981691A (zh) * 2020-11-23 2023-10-31 斯克奥特比奥股份有限公司 抗原结合分子及其用途
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2016198470A2 (en) 2015-06-08 2016-12-15 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
CA2994353A1 (en) * 2015-09-08 2017-03-16 Universitat Zurich Treatment of insect bite hypersensitivity
NZ747512A (en) * 2016-04-27 2023-05-26 Benchmark Animal Health Ltd Treatment of canine atopic dermatitis

Also Published As

Publication number Publication date
JP7250032B2 (ja) 2023-03-31
AU2018383708A1 (en) 2020-07-16
SG11202005526WA (en) 2020-07-29
EP3724218A2 (en) 2020-10-21
JP2021510169A (ja) 2021-04-15
TW201927813A (zh) 2019-07-16
CN111448208B (zh) 2024-02-27
KR20210009296A (ko) 2021-01-26
US20210079054A1 (en) 2021-03-18
CN111448208A (zh) 2020-07-24
BR112020011308A2 (pt) 2020-11-17
RU2020122924A (ru) 2022-01-14
WO2019118512A2 (en) 2019-06-20
CA3085318A1 (en) 2019-06-20
TWI741241B (zh) 2021-10-01
WO2019118512A3 (en) 2020-04-09
AU2018383708B2 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
PH12021551065A1 (en) Fused ring compounds
WO2018234793A3 (en) Antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
WO2017015559A3 (en) Evolution of bt toxins
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EA202190807A1 (ru) Антитела к синуклеину
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
NZ762312A (en) Anti-pacap antibody
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
AU2018279184A1 (en) Anti-TrkB antibodies
WO2018132821A3 (en) Elastomeric proteins
NZ724772A (en) Antibodies against hpa-1a
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2021015501A (es) Anticuerpos y metodos de uso.
WO2024015611A3 (en) Tau peptide immunogen constructs
EA201991653A1 (ru) Изоляты bacillus и варианты их применения
EA202092121A1 (ru) Антитела против cd73 и их применения